Top CRO and CMO M&A activity of 2017
Every week, another merger or acquisition (or so it seemed) as the industry continued to consolidate in 2017.
Every week, another merger or acquisition (or so it seemed) as the industry continued to consolidate in 2017.
The pharmaceutical industry made significant advancements towards global regulatory harmonization in 2017 – despite a highly-charged political environment on both sides of the Atlantic.
Outsourcing models examined, market shifts scrutinized, and trial tribulations analyzed – take a look back at some of the top reports published in 2017.
Commercial transformation could reach new heights in 2018, says inVentiv – as new expectations (and possibilities) reshape traditional models.
A lack of confidence in trial recruitment estimates can cause a “dilemma” for sites bidding for clinical studies, says expert Philipp Bardorrek.
A piece of glass found in a vial of generic injectable product Pantoprazole Sodium has prompted AuroMedics Pharma to issue a nationwide voluntary recall.
Boehringer Ingelheim has partnered with Evox Therapeutics to investigate the delivery of RNA-based drugs in cell-derived vesicles called exosomes.
The US FDA says Elite Pharmaceuticals Inc. has addressed drug safety monitoring shortcomings that earned it a warning letter in 2016.
News in brief
Colorcon Inc. and Applied DNA Sciences Inc. have teamed up to commercialize an on-dose traceability platform they say will help combat counterfeits.
Spark Therapeutics has received US approval for Luxturna (voretigene neparvovec-rzyl), its one-time gene therapy treatment for an inherited form of vision loss.